Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.39 |
| ▸ | EZH1 | Q92800 | 2/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499844 | 0.88 | CMKLR1 (0.41) | CMKLR1MERTKALDH1A1TP53IRAK4 | |
| SCHEMBL20162102 | 0.87 | PDE9A (0.41) | CMKLR1EZH1ESR1EZH2PDE9A | |
| SCHEMBL12499160 | 0.84 | S1PR1 (0.42) | CMKLR1EZH1MERTKEZH2ALDH1A1 | |
| SCHEMBL2594073 | 0.80 | OPRK1 (0.50) | OPRK1 | |
| SCHEMBL2591349 | 0.80 | OPRK1 (0.46) | ALDH1A1OPRK1PDE9ACYP11B2 | |
| SCHEMBL15997907 | 0.78 | CYP11B2 (0.50) | MERTKALDH1A1TP53NR4A2PDE9A | |
| SCHEMBL12499973 | 0.77 | S1PR1 (0.45) | MERTKALDH1A1PDE9A | |
| SCHEMBL12499544 | 0.77 | CYP11B2 (0.40) | ALDH1A1OPRK1PDE9ACYP11B2 | |
| SCHEMBL14048916 | 0.74 | GPR119 (0.40) | ALDH1A1NR4A2 | |
| SCHEMBL3955027 | 0.74 | GPR119 (0.54) | EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323820-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3323820-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| US-8962620-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962620-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962620-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8598167-B1 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130317026-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.